Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia

American Journal of Gastroenterology

Volumn 106, Issue 12, 2011, Pages 2204-2206

  Lazaraki, Georgia ^a   Akriviadis, Evangelos ^b   Pilpilidis, Ioannis ^a   Parisi, Ioanna ^a   Tzilves, Dimitrios ^a   Tarpangos, Anestis ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FERRITIN; HEMOGLOBIN; IRON; OCTREOTIDE;

ABSENCE OF SIDE EFFECTS; AGED; BLOOD TRANSFUSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL ENDOSCOPE; GASTROINTESTINAL HEMORRHAGE; HUMAN; LETTER; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; TREATMENT RESPONSE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ENDOSCOPY, GASTROINTESTINAL; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HUMANS; IRON; LIVER; RECURRENCE; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 82955225211     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.287     Document Type: Letter

References (13)

1. Begbie ME, Wallace GM, Shovlin CL. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 2003; 79: 18-24. (Pubitemid 36237873)
2. Sadick H, Riedel F, Naim R et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factorbeta1 as well as high ALK1 tissue expression. Haematologica 2005; 90: 818-28.
3. Cirulli A, Liso A, D' Ovidio F et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003; 110: 29-32. (Pubitemid 37140401)
4. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia aft er treatment with VEGF antagonist bevacizumab. Ann Hematol 2006; 85: 631-2. (Pubitemid 44283088)
5. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143-4.
6. Retornaz F, Rinaldi Y, Duvoux C. More on bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 361: 931.
7. Mitchell A, Adams LA, MacQuillan G et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008; 14: 210-3. (Pubitemid 351267278)
8. Fodstad P, Dheyauldeen S, Rinde M et al. Anti-VEGF with 3-week intervals is eff ective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 2011; 90: 611-2.
9. Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2011; 364: 688-9.
10. Lu JF, Bruno R, Eppler S et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-86.
11. Buscarini E, Manfredi G, Zambelli A. Bevacizumab to treat complicated liver vascular malformations in hereditary hemorrhagic telangiectasia: a word of caution. Liver Transpl 2008; 14: 1685-6.
12. Bergsland E, Dickler MN. Maximizing the potential of bevacizumab in cancer treatment. Oncologist 2004; 9 (Suppl 1): 36-42. (Pubitemid 38747846)
13. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50. (Pubitemid 32119100)